164 related articles for article (PubMed ID: 35859633)
1. Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies.
Behbehani R; Ali A; Al-Moosa A
Neuroophthalmology; 2022; 46(4):220-226. PubMed ID: 35859633
[TBL] [Abstract][Full Text] [Related]
2. Single-fiber Electromyography in the Extensor Digitorum Communis for the Predictive Prognosis of Ocular Myasthenia Gravis: A Retrospective Study of 102 Cases.
Guan YZ; Cui LY; Liu MS; Niu JW
Chin Med J (Engl); 2015 Oct; 128(20):2783-6. PubMed ID: 26481746
[TBL] [Abstract][Full Text] [Related]
3. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma.
Supawongwattana M; Vanikieti K; Jindahra P; Padungkiatsagul T
Clin Ophthalmol; 2023; 17():649-656. PubMed ID: 36875532
[TBL] [Abstract][Full Text] [Related]
4. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
5. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
6. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
[TBL] [Abstract][Full Text] [Related]
7. Characterization of patients with ocular myasthenia gravis - A case series.
Karni A; Asmail A; Drory VE; Kolb H; Kesler A
eNeurologicalSci; 2016 Sep; 4():30-33. PubMed ID: 29430546
[TBL] [Abstract][Full Text] [Related]
8. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
9. Low conversion rate of ocular to generalized myasthenia gravis in Singapore.
Teo KY; Tow SL; Haaland B; Gosavi TD; Jing-Liang L; Yew Long LO; Milea D
Muscle Nerve; 2018 May; 57(5):756-760. PubMed ID: 28981152
[TBL] [Abstract][Full Text] [Related]
10. Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.
Zhang J; Zhang Z; Zhang H; Cui Y; Chen Y; Lv P; Zhang P
Orphanet J Rare Dis; 2022 Aug; 17(1):309. PubMed ID: 35945595
[TBL] [Abstract][Full Text] [Related]
11. Ocular myasthenia gravis: predictive value of single-fiber electromyography.
Weinberg DH; Rizzo JF; Hayes MT; Kneeland MD; Kelly JJ
Muscle Nerve; 1999 Sep; 22(9):1222-7. PubMed ID: 10454717
[TBL] [Abstract][Full Text] [Related]
12. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
13. Oxidative modifications of blood serum proteins in myasthenia gravis.
Adamczyk-Sowa M; Bieszczad-Bedrejczuk E; Galiniak S; Rozmiłowska I; Czyżewski D; Bartosz G; Sadowska-Bartosz I
J Neuroimmunol; 2017 Apr; 305():145-153. PubMed ID: 28284335
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
15. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
16. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
17. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
18. Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.
Zhao S; Yan X; Ding J; Ren K; Sun S; Lu J; Zhang C; Zhang K; Li Z; Guo J
Front Neurol; 2022; 13():857402. PubMed ID: 35547386
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Gaze Photographs in Diagnosing Ocular Myasthenia Gravis.
Ahn J; Park KS; Kim JS; Hwang JM
J Clin Neurol; 2018 Jul; 14(3):333-338. PubMed ID: 29856158
[TBL] [Abstract][Full Text] [Related]
20. Antibody profile may predict outcome in ocular myasthenia gravis.
Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
